Approval · Notice of Compliance 37217 · 2026
SUMATRIPTAN INJECTION, USP: Notice of Compliance 37217
Issued March 27, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37217
- Date
- March 27, 2026
- Company
- Dr Reddys Laboratories Ltd
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to Product Monograph
- Canadian reference product
- IMITREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SUMATRIPTAN INJECTION, USP | Not yet assigned | — |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 6 MG per 0.5ML